Quid Pro Quo? FDA Architect of Preemption gets hired by Glaxo
Ed Silverman describes Daniel Troy as the preemption prince - I can't think of a better name for him myself:
The preemption prince is joining the big drugmaker as senior vice president and general counsel on September 2. This is a coup for Glaxo, because Troy is widely known - some might say notorious - for being supportive of the pharmaceutical industry.
During his tenure as FDA chief counsel, Troy instructed agency staff to issue fewer warning letters in the belief that the missives were being ignored, which resulted critics say led to less effective enforcement of advertising violations. He also laid the groundwork for the current legal battle over preemption, which says FDA approval supercedes state law claims challenging safety, efficacy, or labeling. Drugmakers and the FDA argue preemption exists by maintaining agency actions are the final word on safety and effectiveness.
One would assume that Troy's salary at GSK will be much higher than his salary at the FDA. Whatever his salary will be, he'll be underpaid if his preemption policy is approved by the Supreme Court.
Wouldn't it be nice if all regulatory agencies had a one or two year window before employees can go join the companies they used to regulate? Most people support those restrictions for lobbyists, so why not for other employees who also have undue influence over governmental affairs?
UPDATE: I mistakenly thought Troy left FDA in 11/06 - Thanks to Ted Frank for pointing out it was 11/04, so a two-year window wouldn't have applied to him in this case. Regardless, I'm still troubled by the "revolving door" between pharma and FDA.